Pittenger & Anderson Inc’s Opko Health OPK Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$375 Hold
250
﹤0.01% 499
2026
Q1
$285 Hold
250
﹤0.01% 513
2025
Q4
$315 Hold
250
﹤0.01% 502
2025
Q3
$388 Hold
250
﹤0.01% 447
2025
Q2
$330 Hold
250
﹤0.01% 414
2025
Q1
$415 Hold
250
﹤0.01% 416
2024
Q4
$368 Hold
250
﹤0.01% 425
2024
Q3
$373 Hold
250
﹤0.01% 445
2024
Q2
$313 Hold
250
﹤0.01% 436
2024
Q1
$300 Hold
250
﹤0.01% 420
2023
Q4
$378 Hold
250
﹤0.01% 424
2023
Q3
$400 Hold
250
﹤0.01% 409
2023
Q2
$543 Hold
250
﹤0.01% 447
2023
Q1
$365 Hold
250
﹤0.01% 429
2022
Q4
$312 Hold
250
﹤0.01% 426
2022
Q3
$0 Hold
250
﹤0.01% 474
2022
Q2
$1K Hold
250
﹤0.01% 424
2022
Q1
$1K Hold
250
﹤0.01% 442
2021
Q4
$1K Hold
250
﹤0.01% 443
2021
Q3
$1K Hold
250
﹤0.01% 428
2021
Q2
$1K Hold
250
﹤0.01% 399
2021
Q1
$1K Hold
250
﹤0.01% 388
2020
Q4
$1K Hold
250
﹤0.01% 367
2020
Q3
$1K Hold
250
﹤0.01% 359
2020
Q2
$1K Buy
+250
New +$560 ﹤0.01% 355

Other funds holding OPK

Pittenger & Anderson Inc's OPK Position: Q2 2026 in Review

Pittenger & Anderson Inc held its Opko Health (OPK) position steady in Q2 2026 at 250 shares worth $375. The position accounts for ﹤0.01% of the portfolio, ranked #499.

Pittenger & Anderson Inc first reported a position in OPK in Q2 2020 and has held it in 25 quarters since. The position peaked at $1K in Q2 2022. 223 funds tracked by Wall St. Rank hold OPK as of Q2 2026.

  • Pittenger & Anderson Inc held 250 shares of Opko Health worth $375 as of Q2 2026.
  • Pittenger & Anderson Inc left its Opko Health share count unchanged in Q2 2026.
  • Opko Health made up ﹤0.01% of Pittenger & Anderson Inc's portfolio in Q2 2026, its #499 holding.
  • Pittenger & Anderson Inc first reported a position in Opko Health in Q2 2020 and has held it in 25 quarters since.
  • Pittenger & Anderson Inc's Opko Health position peaked at $1K in Q2 2022.
  • 223 funds tracked by Wall St. Rank held Opko Health as of Q2 2026.

Based on Pittenger & Anderson Inc's 13F filing for Q2 2026, filed 27 Jul 2026.